COMPANY
Alveolus Bio
NIH awards 5
- NIH award 1R43AI191900-01A1 FY2026: $273,123 awarded for that fiscal year; activity R43 (SBIR); PI NICOLA, TEODORA; recipient as written: ALVEOLUS BIO, INC., BIRMINGHAM, AL. An Inhaled Live Biotherapeutic for Influen source ↗
- NIH award 1R43AI197548-01 FY2026: $301,768 awarded for that fiscal year; activity R43 (SBIR); PI NICOLA, TEODORA; recipient as written: ALVEOLUS BIO, INC., BIRMINGHAM, AL. Leveraging Live Biotherapeutics for the Trea source ↗
- NIH award 5R44HL164156-04 FY2025: $992,385 awarded for that fiscal year; activity R44 (SBIR); PI NICOLA, TEODORA; recipient as written: ALVEOLUS BIO, INC., BIRMINGHAM, AL. An Inhaled Microbiome-Targeted Biotherapeuti source ↗
- NIH award 4R44HL164156-03 FY2024: $999,425 awarded for that fiscal year; activity R44 (SBIR); PI NICOLA, TEODORA; recipient as written: ALVEOLUS BIO, INC., BIRMINGHAM, AL. An Inhaled Microbiome-Targeted Biotherapeuti source ↗
- NIH award 6R44HL164156-02 FY2023: $3,297 awarded for that fiscal year; activity R44 (SBIR); PI NICOLA, TEODORA; recipient as written: ALVEOLUS BIO, INC., BIRMINGHAM, AL. An Inhaled Microbiome-Targeted Biotherapeutic source ↗
Funding and NIH signals
- NIH award NIH awarded $273K (SBIR Phase I 1R43AI191900-01A1, new, notice Sep 11, 2026); 2 NIH awards totaling $575K in the last 12 months. NIH RePORTER 1R43AI191900-01A1 (Sep 11, 2026)
Evidence (2 events)
- Sep 11, 2026 · NIH RePORTER 1R43AI191900-01A1
Organization: ALVEOLUS BIO, INC.; City/State: BIRMINGHAM, AL; Project number: 1R43AI191900-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 273123; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: An Inhaled Live Biotherapeutic for Influenza Viral Infection; Organization type: Domestic For-Profits - Aug 18, 2026 · NIH RePORTER 1R43AI197548-01
Organization: ALVEOLUS BIO, INC.; City/State: BIRMINGHAM, AL; Project number: 1R43AI197548-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 301768; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Leveraging Live Biotherapeutics for the Treatment of Chronic Rhinosinusitis; Organization type: Domestic For-Profits
- Sep 11, 2026 · NIH RePORTER 1R43AI191900-01A1